A comparative study of the analgesic and antipyretic effect of the interleukin-1 receptors recombinant antagonist
DOI:
https://doi.org/10.24959/cphj.15.1368Keywords:
raleukin, acetic acid convulsions, milk fever, antipyretic, analgesic effectAbstract
In recent years the speical attention was focused on the problem of effective and safe anti-inflammatory drugs creation and introduction into medical practice. According to the modern concepts the activation of cytokines is one of the inflammatory process triggers. So the correction of quantitative, qualitative and functional disorders of cytokine regulation, in particular by blocking the receptors that are sensitive to the cytokines, such as interleukin-1 (IL-1), is one of the promising areas of the modern anti-inflammatory therapy. The article presents the results of the comparative experimental study of the raleukin IL-1 receptors recombinant antagonist analgesic and antipyretic properties. It was found that on the model of acetic acid convulsions in mice raleukin showed the moderate analgesic activity, which is considerably inferior to analginium. However, it is necessary to note that raleukin showed the analgesic effect in the dose 3 mg / kg, which is 17 times less than the dose of the reference drug. On the model of milk fever in rats raleukin showed the expressed antipyretic effect in preventive input mode and the moderate one in the medical input. The difference in the severity of antipyretic activity of the drug at the various input modes can probably be explained by the fact that during the medical regime we are dealing with the consequences of the IL-1 propirogenic effect as the result of cytokin stage launch, so blocking IL-1 receptor in this case does not affect the severity of the process, which is already running. And the preventive raleukin introduction allows to slow down the beginning of the cytokine cascade launch. The fixed pharmacological raleukin properties allow to considerate this drug as a promising anti-inflammatory agent, makes reasonable the further deep experimental study with the aim to determine the features of its therapeutic effect.
References
Бабак О.Я. Применение нестероидных противовоспалительных средств в терапии / О.Я. Бабак, И.И. Князькова, И.А. Нестерцова // Український тера-певтичний журн.– 2007.– № 2.– С. 4–11.
Доклінічні дослідження лікарських засобів : метод. рек. / за ред. член–кор. АМН України О.В. Стефанова. – К.: Авіценна, 2001. – 528 с.
Кетлинский С. А. Цитокины / С. А. Кетлинский, А. С. Симбирцев. – СПб. : ООО «Издательство Фолиант», 2008. – 552 с.
Ковалева О.Н. Биологические эффекты интерлейкина–1 / О.Н. Ковалева, Т.Н. Амбросова // Врач. практ.– 2001.– № 2.– С. 94–98.
Коваленко Є. М. Фармакологічне вивчення протизапальної активності анта-гоніста рецепторів інтерлейкіна-1 (АРІЛ-1) : автореф. дис. на здобуття наук. ступеня канд. фарм. наук за специальністю 14.03.05 – фар¬мако¬логія / Є. М. Коваленко. – Х., 2009 – 19 с.
Масычева В.И. Разработка препаратов на основе генно–инженерных цито-кинов / В.И. Масычева, Н.М. Пустошилова, Е.Д. Даниленко // Мед. имму-нол.– 2001.– Т. 3, № 3.– С. 369–378.
Сигидин Я. А. Биологическая терапия в ревматологии / Я. А. Сигидин, Г. В. Лукина. – 2-е изд., доп. – М. : Практическая медицина, 2009. – 302 с.
Современные представления о механизмах терапевтического и побочного действия НПВС / В. Мамчур, Е. Подплетняя, О.Макаренко и др. // Вісник фармакології та фармації. – 2005. – №4. – С. 3–17.
Штрыголь С.Ю. Фармакологические свойства и проблемы безопасности применения НПВП – селективных и специфических ингибиторов циклоок-сигеназы-2 / С.Ю. Штрыголь // Провизор.– 2005.– №2.– С. 37-42.
Щокіна К.Г. Органотропні ефекти рекомбінантного антагоніста рецепторів інтерлейкіну-1 (експериментальне дослідження) : дис. на здобуття наук. сту-пеня доктор фарм. наук за специальністю 14.03.05 – фар¬мако¬логія / К. Г. Щокіна. – Х., 2011. – 444 с.
Braddock M. Targeting IL-1 in inflammatory disease: new opportunities for the-rapeutic intervention / M. Braddock, A. Quinn // Nat. Rev. Drug Discov. – 2004. – N. 3. – P. 330-339.
Bresnihan B. Interleukin-1 receptor antagonist / B.Bresnihan, G.Cunnane // Rheumatic Disease Clinics of North America.– 1998.– Vol.24, №3.- P.615-628.
Charles A. The Role of the Interleukein–1–Receptor Antagonist in Blocking In-flammation Mediated by Interleukein–1 / A. Charles, M.D. Dinarello // N. Engl. J. Med.– 2000.– Vol.343, №10.– P. 732-734.
Dinarello C. A. Blocking IL-1 in systemic inflammation / C. A. Dinarello // JEM.– 2005.– Vol. 201, N. 9.– P. 1355-1359.
Downloads
Published
Issue
Section
License
Copyright (c) 2015 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
